ERS International Congress, Madrid, 2019: highlights from the Pulmonary Vascular Diseases Assembly.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
25
05
2020
accepted:
28
08
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
22
10
2020
Statut:
epublish
Résumé
The 2019 European Respiratory Society (ERS) International Congress, held in Madrid, Spain, had exciting sessions regarding the field of pulmonary vascular disease. The symposia related to the new ERS/European Society of Cardiology (ESC) Guidelines for the diagnosis and management of acute pulmonary embolism were well received, as were sessions on pulmonary hypertension related to lung disease, demonstrating the concept of pulmonary hypertension not being the rarity that it was previously thought to be. The use of risk stratification in relation to pulmonary arterial hypertension (PAH) was heavily featured and the scientific sessions informing the respiratory community of potential biomarkers and targets for future therapies were thought-provoking. This article discusses highlights of the 2019 pulmonary vascular disease sessions as a summary of current knowledge and practice. We have summarised the key points from the sessions pertaining to the new ERS/ESC Guidelines for the management of acute pulmonary embolism. We have also focused on prognostic factors and potential therapies in pulmonary hypertension related to interstitial lung disease. Relating to PAH, we have reviewed the symposia on risk stratification, along with the use of noninvasive measures and the sessions relating to biomarkers in PAH.
Identifiants
pubmed: 33083438
doi: 10.1183/23120541.00304-2020
pii: 00304-2020
pmc: PMC7553109
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Informations de copyright
Copyright ©ERS 2020.
Déclaration de conflit d'intérêts
Conflict of interest: S. Ramjug reports nonfinancial support from Janssen, and grants and nonfinancial support from Actelion, during the writing of the manuscript. Conflict of interest: J. Weatherald reports grants, personal fees and nonfinancial support from Janssen Inc. and Actelion, personal fees and nonfinancial support from Bayer, personal fees from Novartis, and grants from the Alberta Lung Association, the Canadian Vascular Network, the European Respiratory Society and the Canadian Thoracic Society, outside the submitted work. Conflict of interest: S. Sahay reports personal fees and nonfinancial support from Bayer Pharmaceuticals, United Therapeutics, Actelion Pharmaceuticals, and Liquidia. Conflict of interest: J. Khoury has nothing to disclose. Conflict of interest: V. Foris has nothing to disclose. Conflict of interest: N. Chandran has nothing to disclose. Conflict of interest: A. Bokan has nothing to disclose. Conflict of interest: L. Godinas has nothing to disclose. Conflict of interest: M. Delcroix reports grants and personal fees from Actelion, and personal fees from Bayer, GSK, MSD, Reata, Bellarophon and Eli Lilly, outside the submitted work.
Références
Am J Respir Crit Care Med. 2007 Dec 1;176(11):1154-60
pubmed: 17872491
J Clin Oncol. 2018 Jul 10;36(20):2017-2023
pubmed: 29746227
Thorax. 2018 Jul;73(Suppl 2):ii1-ii29
pubmed: 29898978
PLoS One. 2020 Feb 28;15(2):e0229409
pubmed: 32109943
Front Physiol. 2019 May 27;10:651
pubmed: 31191349
J Cardiovasc Pharmacol. 2001 Apr;37(4):489-92
pubmed: 11300662
J Heart Lung Transplant. 2019 Jul;38(7):748-756
pubmed: 31128966
Thromb Haemost. 2013 Jul;110(1):83-91
pubmed: 23677493
Am J Physiol Lung Cell Mol Physiol. 2015 May 15;308(10):L1002-13
pubmed: 25840998
JCI Insight. 2017 Mar 9;2(5):e91327
pubmed: 28289720
Respir Med. 2019 Apr;150:126-130
pubmed: 30961938
Am J Respir Crit Care Med. 2015 Jan 15;191(2):208-18
pubmed: 25489667
Ann Intern Med. 2018 Dec 4;169(11):766-773
pubmed: 30357273
J Nucl Med. 2014 Aug;55(8):1273-80
pubmed: 24876205
Am J Respir Crit Care Med. 2019 Dec 15;200(12):1505-1512
pubmed: 31365829
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545980
JAMA. 2014 Mar 19;311(11):1117-24
pubmed: 24643601
BMJ. 2013 Jan 15;346:e8632
pubmed: 23321489
Thorax. 2011 Apr;66(4):326-32
pubmed: 21297151
Curr Opin Pulm Med. 2019 Sep;25(5):459-467
pubmed: 31365380
Heart. 2011 Jul;97(13):1054-60
pubmed: 21558476
N Engl J Med. 2014 Apr 10;370(15):1402-11
pubmed: 24716681
J Pharm Pract. 2020 Oct;33(5):708-711
pubmed: 31216929
N Engl J Med. 2018 Nov 1;379(18):1722-1731
pubmed: 30220235
Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):13122-13130
pubmed: 31152133
N Engl J Med. 2019 Mar 21;380(12):1139-1149
pubmed: 30893534
N Engl J Med. 2018 Feb 15;378(7):615-624
pubmed: 29231094
Breathe (Sheff). 2019 Sep;15(3):241-243
pubmed: 31508162
Int J Cardiol. 2011 Dec;154 Suppl 1:S54-60
pubmed: 22221974
Crit Care Med. 2018 Oct;46(10):1617-1625
pubmed: 29979222
Chest. 2020 Jan;157(1):89-98
pubmed: 31351047
Chest. 2020 Jan;157(1):162-172
pubmed: 31563497
Pediatr Cardiol. 2015 Jun;36(5):1062-9
pubmed: 25737007
Circulation. 2012 Jul 24;126(4):448-54
pubmed: 22679142
Eur Respir J. 2015 Oct;46(4):903-75
pubmed: 26318161
Eur Heart J. 2019 Mar 14;40(11):902-910
pubmed: 30590531
Eur Respir J. 2019 Oct 9;54(3):
pubmed: 31473594
Eur Respir J. 2009 Feb;33(2):325-31
pubmed: 18799507
Circulation. 2011 Nov 1;124(18):1973-81
pubmed: 21969018
J Am Coll Cardiol. 2011 Jul 12;58(3):300-9
pubmed: 21737024
Cardiol Res Pract. 2019 Aug 14;2019:3741909
pubmed: 31485349
J Am Coll Cardiol. 2017 Sep 26;70(13):1587-1597
pubmed: 28935036
Genetics. 2013 Mar;193(3):651-69
pubmed: 23463798
Lancet. 2017 Jul 15;390(10091):289-297
pubmed: 28549662
Chest. 2019 Aug;156(2):323-337
pubmed: 30772387